SGMO Stock Impact Report for 11/13/2024
SGMO Stock Impact Report for 11/13/2024 | News Quantified
Discover the stock impact of the latest SGMO news. Sangamo Therapeutics Reports Recent Business Highlights And Third Quarter 2024.
Sangamo Therapeutics Reports Recent Business Highlights and ...
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in ...
Sangamo Therapeutics reports progress in gene therapies
According to InvestingPro data, Sangamo's market capitalization stands at $564.28 million, reflecting investor interest in the company's ...
Sangamo Therapeutics, Inc. (SGMO) Stock Price, News, Quote ...
Find the latest Sangamo Therapeutics, Inc. (SGMO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights
Upfront License Fees and Milestone Payments: Received $50 million from Genentech. · Cash Runway: Sufficient to fund operations into the first ...
Sangamo Biosciences: Promising Financial Position and Strategic ...
Nov. 13, 2024, 06:55 PM. Related Stocks. SGMO. 2.44. -0.27 (-9.96%). 08:00:00 PM ... Sangamo reports Q3 EPS 4c, consensus (3c) · Sangamo options imply 21.0% ...
SGMO SEC Filings Report for 11/13/2024 | News Quantified
Discover the SEC EDGAR filings impact for SGMO. Form Sc 13g/A Sangamo Therapeutics Filed By Vanguard Group Inc.
Sangamo Therapeutics, Inc. Common Stock (SGMO) Earnings
Common Stock is expected* to report earnings on 11/12/2024 after market close. The report will be for the fiscal Quarter ending Sep 2024. According to Zacks ...
Sangamo Therapeutics, Inc. (SGMO) Stock Historical Prices & Data
ETF Report · Sports · Fantasy · News · Fantasy football · Best Ball · Pro Pick 'Em ... Nov 13, 2024, 2.2500, 2.8100, 2.2500, 2.4750, 2.4750, 8,858,748. Nov 12, ...
Sangamo Therapeutics (SGMO) | Historical & Forecast Data - Trefis
Better Bet Than SGMO Stock: Stocks NSSC, ARGO, AEIS, VICI Look More Promising Than Sangamo Therapeutics · Better Bet Than SGMO Stock: Industry Peers DNLI, MRNA, ...
Sangamo Biosciences: Buy Rating Supported by Promising Fabry ...
Barclays analyst Gena Wang has maintained their bullish stance on SGMO stock, giving a Buy rating on November 5.
News Releases | Investor Relations - Sangamo Therapeutics, Inc.
RICHMOND, Calif. --(BUSINESS WIRE)--Mar. 12, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the ...
SGMO - Sangamo Therapeutics, Inc. Stock - Stock Price, Institutional ...
The share price as of November 13, 2024 is 2.44 / share. Previously, on ... In addition to reporting standard equity and debt issues, institutions with ...
Sangamo Therapeutics Inc. Stock Quote (U.S. - SGMO - MarketWatch
Q3 2024 Sangamo Therapeutics Inc Earnings Call Transcript. Nov. 13, 2024 at 12:06 a.m. ET on GuruFocus.com. Sangamo Therapeutics Reports Strong Q3 2024 Growth.
Sangamo Therapeutics (SGMO) Stock Price, News & Analysis
Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.07) per share. Price to Earnings Ratio vs. the Market. The P/ ...
Sangamo Biosciences Stock Price Forecast. Should You Buy SGMO?
Given the current short-term trend, the stock is expected to rise 107.34% during the next 3 months and, with a 90% probability hold a price between $2.73 and ...
Is Sangamo Therapeutics Inc Stock (SGMO) a Good Investment? - AAII
does not currently pay a dividend. Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions.
Sangamo Therapeutics, Inc. (SGMO) Stock Forecast & Price Targets
The 2 analysts with 12-month price forecasts for SGMO stock have an average target of 6.00, with a low estimate of 2.00 and a high estimate of 10. The average ...
Sangamo Therapeutics (SGMO) News Today - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 6,620 call ...
Sangamo Therapeutics (Nasdaq:SGMO) - Stock Price, News ...
New major risk - Revenue and earnings growth. Nov 13 ; Consensus revenue estimates fall by 17%. Nov 07 ; Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on ...